Agios Pharmaceuticals Inc (AGIO) Insider Sells $354,090.00 in Stock

Agios Pharmaceuticals Inc (NASDAQ:AGIO) insider Scott Biller sold 6,438 shares of the firm’s stock in a transaction on Monday, March 20th. The shares were sold at an average price of $55.00, for a total value of $354,090.00. Following the completion of the sale, the insider now owns 21,403 shares in the company, valued at $1,177,165. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Agios Pharmaceuticals Inc (NASDAQ:AGIO) opened at 55.27 on Monday. Agios Pharmaceuticals Inc has a 12-month low of $34.31 and a 12-month high of $67.74. The firm’s market capitalization is $2.33 billion. The company’s 50-day moving average price is $50.03 and its 200-day moving average price is $49.76.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings data on Thursday, February 16th. The biopharmaceutical company reported ($1.34) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.51) by $0.17. The business had revenue of $22.65 million for the quarter, compared to analysts’ expectations of $10.89 million. Agios Pharmaceuticals had a negative return on equity of 53.39% and a negative net margin of 341.56%. Agios Pharmaceuticals’s quarterly revenue was up 264.5% on a year-over-year basis. During the same period in the previous year, the business posted ($1.08) earnings per share. Equities analysts expect that Agios Pharmaceuticals Inc will post ($7.31) EPS for the current fiscal year.

Insider Buying and Selling by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)

COPYRIGHT VIOLATION WARNING: “Agios Pharmaceuticals Inc (AGIO) Insider Sells $354,090.00 in Stock” was originally posted by Mideast Time and is owned by of Mideast Time. If you are reading this piece of content on another domain, it was illegally stolen and reposted in violation of international copyright & trademark law. The original version of this piece of content can be accessed at https://www.mideasttime.com/agios-pharmaceuticals-inc-agio-insider-sells-354090-00-in-stock/1588953.html.

A number of equities research analysts recently weighed in on AGIO shares. Needham & Company LLC restated a “buy” rating and set a $60.00 price objective on shares of Agios Pharmaceuticals in a research note on Wednesday, December 7th. Canaccord Genuity restated a “buy” rating and set a $90.00 price objective on shares of Agios Pharmaceuticals in a research note on Monday, December 5th. Cowen and Company restated a “buy” rating on shares of Agios Pharmaceuticals in a research note on Monday, January 9th. Janney Montgomery Scott upgraded shares of Agios Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $57.00 price objective on the stock in a research note on Thursday, February 16th. Finally, Oppenheimer Holdings Inc. set a $75.00 price objective on shares of Agios Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, February 16th. Four research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $63.54.

Several hedge funds have recently added to or reduced their stakes in AGIO. Utah Retirement Systems boosted its stake in Agios Pharmaceuticals by 7.8% in the third quarter. Utah Retirement Systems now owns 5,500 shares of the biopharmaceutical company’s stock worth $290,000 after buying an additional 400 shares in the last quarter. OMERS ADMINISTRATION Corp boosted its stake in Agios Pharmaceuticals by 8.0% in the third quarter. OMERS ADMINISTRATION Corp now owns 5,400 shares of the biopharmaceutical company’s stock worth $285,000 after buying an additional 400 shares in the last quarter. Ray Gerald L & Associates Ltd. boosted its stake in Agios Pharmaceuticals by 2.5% in the third quarter. Ray Gerald L & Associates Ltd. now owns 35,315 shares of the biopharmaceutical company’s stock worth $1,865,000 after buying an additional 850 shares in the last quarter. Rhumbline Advisers boosted its stake in Agios Pharmaceuticals by 3.4% in the third quarter. Rhumbline Advisers now owns 29,800 shares of the biopharmaceutical company’s stock worth $1,574,000 after buying an additional 985 shares in the last quarter. Finally, State of Wisconsin Investment Board boosted its stake in Agios Pharmaceuticals by 7.0% in the third quarter. State of Wisconsin Investment Board now owns 19,770 shares of the biopharmaceutical company’s stock worth $1,044,000 after buying an additional 1,300 shares in the last quarter. Institutional investors and hedge funds own 88.79% of the company’s stock.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

5 Day Chart for NASDAQ:AGIO

Receive News & Ratings for Agios Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply

 
© 2006-2017 Mideast Time.